Swift Biosciences, Inc. today announced the launch of the Accel-NGS™ DNA Library Kit, the first product in a new line of kits for Next Generation Sequencing (NGS) sample preparation. NGS users can now produce PCR-free libraries with as little as 5 ng of input DNA. The highly efficient Swift adaptation technology eliminates the need for PCR, thereby minimizing base composition bias and fidelity issues while reducing the input requirement. The unique, two-step adaptation process also reduces adapter dimer formation to maximize sequencing output. Unlike other kits, the Accel-NGS DNA Library Kit does not require intact double-stranded DNA, making it ideal for FFPE and damaged samples.
The Accel-NGS DNA Library Kit protocol is fast, requiring only 75 minutes start-to-finish, and consists of 5 easy step, two of which are bead-based separations that eliminate the need for time-consuming, electrophoretic gel-based size selection. In addition, the streamlined Accel-NGS workflow can be easily automated.
To learn more about how Accel-NGS accelerates NGS library preparation, please visit www.swiftbiosci.com.
About Swift Biosciences
Swift Biosciences is a small, fast-moving company focused on developing innovative enabling technologies for genomics and personalized medicine. With the launch of the first Accel-NGS product, Swift is now applying its unique technologies to the Next Generation Sequencing market. Swift is working diligently to improve NGS sample preparation, an area that has not kept pace with the significant improvements made recently in NGS instrumentation and bioinformatics. Additional Accel-NGS products will be launched in the near future.
The company also has products for qPCR detection of mutations. Swift’s first products, launched in 2012, are based on myT® Primer technology which provides both high sensitivity and specificity in somatic mutation detection, making it ideal for cancer research and diagnostic applications. To date, Swift has developed myT Primers for common mutations in the BRAF and KRAS genes, which demonstrate the superior performance capabilities of the technology. Additional myT Primer reagents will be launched in 2013.
In December of 2012, Swift announced a technology license agreement with the Singapore-based parent of Vela Diagnostics. The agreement gives Vela non-exclusive rights to utilize Swift’s myT Primer technology in Vela’s real-time quantitative PCR-based IVD products for the detection of somatic mutations in human cancer. Vela will seek regulatory approval around the world for its assay kits while Swift will continue to develop myT Primers for RUO applications as well as license to other partners.
Contact
Steve Spotts
Chief Commercial Officer
Swift Biosciences, Inc.
58 Parkland Plaza
Suite 100
Ann Arbor, MI 48103
734.330.2568
